Belite Bio Files for Tinlarebant Approval in Singapore, UK, and Switzerland

Key Facts

Belite Bio submitted Marketing Authorization Applications for tinlarebant in Singapore, the United Kingdom, and Switzerland for the treatment of Stargardt disease type 1. Reuters reported that the company initiated the regulatory submissions for its oral therapy through the Access Consortium framework, aiming to address unmet medical needs for this rare retinal condition.

BLTE closed at $151.87 on October 13, 2026, having reached a day high of $161 and a low of $150.93. These regulatory filings represent a significant milestone for the clinical-stage firm as it seeks to introduce the first approved treatment for the disease in these jurisdictions, following the completion of its clinical trial phases.